Last updated: 2026-09-06 15:00:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CRISPR Therapeutics AG (CRSP) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $55.76, with a market capitalization of $5.39B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $44.12 to $78.48. This page covers its latest market performance, valuation, price trends and company information.
$5.39B | |
$56.39 | |
$220.20 | |
$11.63 | |
$56.49 | |
740.95K | |
1.58M | |
-- | |
$78.48 | |
$44.12 | |
-- | |
-- |
CRISPR Therapeutics AG (CRSP) last closed at $56.49 as of 2026-09-05 00:00:00, unchanged from the previous close of $56.49.
During the latest regular trading session, CRSP traded between $11.63 and $220.20, with a volume of 740.95K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, CRISPR Therapeutics AG (CRSP) moved from $59.37 to $55.76, representing a decline of 6.07% ($3.61).
The stock traded between $55.35 and $60.11 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.17 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33.9%
CRSP is currently trading at $55.76, placing it 33.9% of the way from its 52-week low of $44.12 to its 52-week high of $78.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 393 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CRISPR Therapeutics AG (CRSP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.